BofA raised the firm’s price target on Amylyx (AMLX) to $16 from $14 and keeps a Buy rating on the shares after including net proceeds from the follow-on after the company raised $175M, for net proceeds of $163M, by issuing 17.5M shares at a price of $10 each. The balance sheet boost gives the company flexibility to invest in commercial ramp-up activities at or near the time of Phase 3 LUCIDITY trial results readout for avexitide for post-bariatric hypoglycemia, the analyst tells investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMLX:
- Strategic Growth and Financial Flexibility Position Amylyx Pharmaceuticals for Success: Buy Rating with $16 Price Target
- Amylyx price target raised to $25 from $17 at Guggenheim
- Amylyx Pharmaceuticals Announces $164 Million Stock Offering
- Amylyx 17.5M share Spot Secondary priced at $10.00
- Amylyx announces common stock offering, no amount given